期刊文献+

4-1BBL分子在脑胶质瘤组织中的表达及其临床意义 被引量:3

Clinical significance of 4-1BBL protein expression in human glioma tissues
下载PDF
导出
摘要 目的:探讨共刺激分子4-1BBL(CD137L)在胶质瘤组织中的表达及其临床意义。方法:免疫组化方法检测4-1BBL在82例脑胶质瘤组织中的表达,并分析其与病理分级、患者年龄、性别及生存时间的关系。结果:正常3例脑组织标本未见4-1BBL表达。82例胶质瘤标本31例4-1BBL阳性,阳性表达率为37.8%。统计学提示组织标本中4-1BBL表达与病理级别无明显相关性,与年龄有关(P<0.05),4-1BBL阳性患者生存期更长(P<0.05)。结论:4-1BBL在部分胶质瘤组织中有表达,其表达对判断胶质瘤患者的预后有一定的参考价值。 AIM:To investigate the expression of 4-1BBL(CD137L) protein in human glioma tissues,and to analyze its clinical significance.METHODS: The expression levels of 4-1BBL protein in 82 human glioma specimens were measured by the method of immunohistochemistry.The correlation of 4-1BBL protein level with histopathologic features and survival time was analyzed.RESULTS: 4-1BBL protein positive cells were observed in human brain astrocytic tumors,which were not found in meningioma and normal brain tissues.In our study,the expression of 4-1BBL protein in 3 cases of normal brain tissues was negative.The expression of 4-1BBL protein in 31 cases of glioma specimens were positive,and total positive rate was 37.8%(31/82).The expression of 4-1BBL protein was related to the survival time and age of the patients,but not related to the pathological grade of glioma.Statistically,the patients with positive expression of 4-1BBL protein had longer survival time(P0.05).CONCLUSION: Expression of 4-1BBL protein may have reference value to predict the prognosis of patients with glioma.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2010年第12期2342-2346,共5页 Chinese Journal of Pathophysiology
基金 广东省科技计划资助项目(No.20061040645) 广州市科技计划资助项目(No.2007Z3-E4061) 广东省自然科学基金资助项目(No.8151008901000012) 国家自然科学基金资助项目(No.30973080)
关键词 4-1BB配体 神经胶质瘤 预后 4-1BB ligand Glioma Prognosis
  • 相关文献

参考文献22

  • 1江涛,王忠诚.脑胶质瘤的分子靶向治疗[J].中华神经外科杂志,2007,23(9):641-642. 被引量:8
  • 2Eramo A,Ricci-Vitiani L,Zeuner A,et al.Chemotherapy resistance of glioblastoma stem cells[J].Cell Death Differ,2006,13(3):1238-1241.
  • 3Saoulli K,Lee SY,Cananons JL,et al.CD28-independent,TRAF2-dependent costimulation of resting T cells by 4-1BB ligand[J].J Exp Med,1998,187(16):1849-1862.
  • 4苏静,周磊,孔晓霞,郑花,孙连坤.抑制氯通道CLCN2基因表达对顺铂诱导胶质瘤U251细胞损伤的影响[J].中国病理生理杂志,2009,25(5):859-863. 被引量:2
  • 5Bertram EM,Lau P,Watts TH,et al.Temporal segregation of 4-1BB versus CD28-mediated costimulation:4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection[J].J Immunol,2002,168(8):3777-3785.
  • 6Bechmann I,Galea I,Perry VH,et al.What is the blood-brain barrier?[J].Trends Immunol,2007,28(7):5-11.
  • 7Bechmann I,Priller J,Kovac A,et al.Immune surveillance of mouse brain perivascular spaces by blood-borne macrophages[J].Eur J Neurosci,2001,14(10):1651-1658.
  • 8Poduslo JF,Ramakrishnan M,Holasek SS,et al.In vivo targeting of antibody fragments to the nervous system for Alzheimers disease immunotherapy and future science group molecular imaging of amyloid plaques[J].J Neurochem,2007,102(2):420-433.
  • 9Amy RD,William HB,Thomas L,et al.Immune defects observed in patients with primary malignant brain[J].Neuroimmunol,1999,100(1):216-232.
  • 10Brenner AV,Linet MS,Fine HA,et al.History of allergies and autoimmune diseases and risk of brain tumors in adults[J].Int J Cancer,2002,99(2):252-259.

二级参考文献28

共引文献11

同被引文献22

  • 1Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS sta- tistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009 [ J ]. Neuro Oncol, 2012, 14(Suppl 5) :v1-v49.
  • 2Stupp R, Mason WP, van den Bent M J, et al. Radiother- apy plus concomitant and adjuvant temozolomide for glio- hlastoma[J]. N Engl J Med, 2005, 352(10) :987-996.
  • 3Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glio- blastoma? [J]. Neuro Oncol, 2011, 13(1) :3-13.
  • 4Prasad DV, Richards S, Mai XM, et al. B7S1, a novel B7 family member that negatively regulates T cell activa- tion[J], hnmunity, 2003, 18(6) :863-873.
  • 5Sun Y, Wang Y, Zhao J, et al. B7-H3 and B7-H4 ex- pression in non-small-cell lung cancer[ J ], Lung Caneer, 2006, 53(2) :143-151.
  • 6Tringler B, Liu W, Corral L, et al. B7-H4 overexpression in ovarian tumors[J]. Gynecol Oncol, 2006, 100(1 ) :44- 52.
  • 7Jiaqg J, Zhu Y, Wu C, et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer [ J ]. Cancer lmmunol lmmunuther, 2010, 59 ( 11 ) : 1707-1714.
  • 8Zhao JJ, Pan K, Li JJ, el al. Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcino- ma [ J ]. PLnS One, 2011, 6 ( 10 ) : e26608.
  • 9Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA CancerJClin, 2012, 62(1):10-29.
  • 10Chang SM, Butowski NA, Sneed PK, et al. Standard treatment and experimental targeted drug therapy for recur- rent glioblastoma multiforme[ J ]. Neurosurg Focus, 2006, 20(4) :E4.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部